Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lipocalin 2 is protective against E. coli pneumonia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Validation of the IPF-specific version of St. George's Respiratory Questionnaire

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Lipocalin 2 is a bacteriostatic protein that binds the siderophore enterobactin, an iron-chelating molecule produced by Escherichia coli (E. coli) that is required for bacterial growth. Infection of the lungs by E. coli is rare despite a frequent exposure to this commensal bacterium. Lipocalin 2 is an effector molecule of the innate immune system and could therefore play a role in hindering growth of E. coli in the lungs.
OriginalsprogEngelsk
TidsskriftRespiratory Research
Vol/bind11
Udgave nummer96
Sider (fra-til)96
Antal sider8
ISSN1465-9921
DOI
StatusUdgivet - 2010

ID: 32183851